Skip to main content
Caplight Logo









Neurogastrx

Neurogastrx

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://neurogastrx.com/

Last Round

Series B

Aug 26, 2021

Total Funding Raised

$105M

Company Overview

Neurogastrx is a biotechnology company that develops specialized therapies aimed at treating gastrointestinal disorders related to the enteric nervous system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalgastrointestinal disordersgastroparesisGLP-1 agonistssmall-molecule drugenteric nervous systemclinical-stage biotechdopamine D2 antagonistweight-loss drug side-effectsdrug developmentGIclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurogastrx Comparables

Compare Neurogastrx with similar companies based on industry and business-model similarity.

Neurogastrx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CinDome Pharma
91%
Retromer Therapeutics
87%
Renexxion, Inc.
81%

Neurogastrx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 26, 2021
Series AJan 4, 2018

Key People

Founding team and executive leadership

Cyril De Colle

Founder Chief Scientific Officer

Founding Team

James O'Mara

President And CEO

Executive Team

Neurogastrx Investors

Notable investors and investment history

Neurogastrx investors
InvestorRounds
M VenturesSeries B, Series A
OrbiMedSeries B, Series A
5AM VenturesSeries B, Series A
venBioSeries B, Series A
RTW InvestmentsSeries B
Marshall WaceSeries B
Samsara BioCapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2021

    $60M round led by Vivo Capital.

  • Jan 4, 2018

    $45M round led by OrbiMed, 5AM Ventures, and venBio.

Neurogastrx Filings

Explore SEC and related filing metadata, where available.

Neurogastrx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neurogastrx's valuation, stock price, and market status.

Is Neurogastrx a public or private company?

Neurogastrx is a private company.

What is the current stock price of Neurogastrx?

Neurogastrx is a private company with no public stock price. No recent secondary market data is available.

How much is Neurogastrx worth (valuation)?

Valuation information for Neurogastrx is not publicly available.

Can I buy Neurogastrx stock?

Neurogastrx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neurogastrx's last funding round?

Neurogastrx's most recent funding round was Series B on August 26, 2021.

Who are the main investors in Neurogastrx?

Key investors in Neurogastrx include OrbiMed, 5AM Ventures, venBio, Vivo Capital.

Will Neurogastrx IPO soon?

No public IPO plans have been announced for Neurogastrx.

How can I track Neurogastrx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurogastrx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range2
Year Founded2012
Last FundingAug 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?